CA-DIGILENS-INC.
3.4.2023 14:01:30 CEST | Business Wire | Press release
DigiLens Inc., a global leader in waveguide technology, is proud to announce the launch of SRG+, the next level of surface relief gratings (SRG) that advances DigiLens' current industry-leading volume Bragg gratings (VBG) with improved efficiency, uniformity, increased field of view, and compact form factor — all at a low price point, and with the ability to mass produce efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230403005135/en/
SRG+ breakthrough features (Graphic: Business Wire)
The SRG+ process is an extension of DigiLens’ well-established VBG technology. It results in an SRG structure that has no residual bias layer and best-in-class control over the creation of grating angles leading to industry-leading efficiency and minimal eye glow. This enables the highest-performing and most socially acceptable waveguide displays at a consumer price point.
Dr. Bernard Kress, president of SPIE, the international society for optics and photonics, said, “Over the past 50 years, Moore’s law pushed for successive IC fab technology revolutions. Over the past two decades, nanoImprint lithography (NIL) has been a great tool for 3D nanostructure replication, and resonated well with the Wafer Level Optics industry, providing new opportunities from Metalenses to AR waveguide gratings. The need for costly 3D etched masters has been a limitation for its adoption in consumer goods production, especially when the number of AR waveguides is low. With new challenges arising, such as higher aspect ratio high slant nanostructures without any residual layers over large areas, the industry is left with very few options. I am excited about DigiLens’ recent SRG+ developments, which provide a new, low-cost replication technology satisfying such drastic nanostructure requirements. The AR waveguides field is the tip of the iceberg as such novel nanostructures and related cost models create new design and application opportunities ranging from biotechnology to quantum and beyond.”
Features of SRG+ include:
- Higher delta-n: Higher diffraction efficiency and wider angular response
- S&P polarization: Ideal for microLED
- No bias layer: Wider angle response with high index glass
- Tall gratings: Gratings several microns in height with high >10:1 aspect ratios
- Higher efficiency: Brighter/longer battery life
- Wider field of view: Improved AR experience
- Lighter weight: Fewer waveguides
- Smaller footprint: Lighter/easier to style
- Lower cost: Much lower cost of masters needed for manufacturing
- High-performance plastic: Safer/lighter weight
- Fast ramp-up to volume manufacturing: Simple manufacturing processes and fast cycle time for design optimization and waveguide manufacturing
Benefits of SRG+ include:
- 4 times standard SRG waveguide efficiencies at less than half the cost
- Simple process extension to VBG
- Ability to mix and match VBG and SRG+ structures to optimize for the application
- Lowest eye glow metrics
- Near reflective efficiency at a holographic HOE price
“With SRG+, we’ve unlocked the challenges associated with conventional surface relief gratings such as those made by NIL techniques, reaching unprecedented structure heights of many microns and aspect ratios that exceed 10:1, while retaining the low-cost manufacturing methodologies that underpin DigiLens’ technology,” says Alastair Grant, senior vice president of optical engineering, DigiLens Inc.
“Having a high-aspect ratio and no bias layer enables reduced stray light and higher efficiency, which can lead to improved performance of lightguide eye-pieces that enhance visual instruction and training to optimize workforce performance,” said Dave Velasquez, vice president and general manager, Corning® Gorilla® Glass. Corning Incorporated joined DigiLens’ Series D funding round as an investor in 2022. “There’s exciting potential for SRG+ to deliver these important attributes for the future of AR technology.”
About DigiLens
DigiLens is a leader in holographic waveguides used for XR displays. The company has developed a patented optical platform and photopolymer technology that delivers best-in-class solutions using a unique, low-cost contact-copy manufacturing process. DigiLens enables OEM partners to design and build XR-enabled devices for the global automobile, enterprise, consumer, avionics, and military industries. Based in Sunnyvale, CA, DigiLens investors include industry leaders like Samsung Electronics, Samsung Electro-Mechanics, Diamond Edge Ventures, the strategic investment arm of Mitsubishi Chemical Holdings Corporation, Alsop Louie Partners, Optimas Capital Management, 37 Interactive Entertainment, UDC Ventures, the corporate venture arm of Universal Display Corporation, Niantic, Inc., Sony Innovation Fund, Dolby Family Ventures, Continental AG, and more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005135/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
